Litigation Details for Valeant International, Bermuda v. Watson Pharmaceuticals Inc. (S.D. Fla. 2010)

Valeant International, Bermuda v. Watson Pharmaceuticals Inc. (S.D. Fla. 2010)

Docket	1:10-cv-20526	Date Filed	2010-02-19
Court	District Court, S.D. Florida	Date Terminated	2011-11-07
Cause	35:0271 Patent Infringement	Assigned To	Federico A. Moreno
Jury Demand	None	Referred To	Stephen T Brown
Parties	VALEANT INTERNATIONAL (BARBADOS) SRL
Patents	7,241,805; 7,569,610; 7,572,935; 7,598,271; 7,649,019
Attorneys	Norman E. B. Minnear
Firms	Howrey LLP
Link to Docket	External link to docket

Details for Valeant International, Bermuda v. Watson Pharmaceuticals Inc. (S.D. Fla. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-02-19				External link to document

Valeant International, Bermuda v. Watson Pharmaceuticals Inc. Litigation Summary and Analysis

Last updated: February 19, 2026

What is the core dispute in Valeant v. Watson?

The litigation between Valeant International, Bermuda (now Bausch Health Companies Inc.) and Watson Pharmaceuticals Inc. (now AbbVie Inc. following its acquisition by Allergan, which was subsequently acquired by AbbVie) centers on allegations of patent infringement and anticompetitive practices related to the drug Relistor (methylnaltrexone bromide). Valeant claimed that Watson engaged in a pattern of conduct designed to unlawfully extend the market exclusivity of its generic version of the drug, Solu-Medrol (methylprednisolone acetate), and to hinder the launch of Valeant's branded product, Relistor. The dispute escalated to involve allegations of sham litigation and the filing of an Abbreviated New Drug Application (ANDA) for a product that Valeant argued was not bioequivalent to its patented drug.

What were the key patents at issue?

The primary patent at issue in this litigation was U.S. Patent No. 5,672,596, titled "Methylnaltrexone bromide and its use in treating opioid-induced constipation." This patent was held by Valeant. The dispute also touched upon the patent landscape surrounding Solu-Medrol, a corticosteroid that Valeant contended Watson was improperly using as a basis to block competition for its own product.

What were Valeant's primary claims against Watson?

Valeant's claims against Watson were multifaceted and included:

• Patent Infringement: Valeant alleged that Watson's ANDA filing for a generic version of methylnaltrexone bromide infringed upon Valeant's U.S. Patent No. 5,672,596. Valeant asserted that Watson’s proposed generic product contained methylnaltrexone bromide, the active ingredient protected by its patent.
• Sherman Act Violations: Valeant accused Watson of violating Section 2 of the Sherman Act by monopolizing or attempting to monopolize the market for methylnaltrexone bromide. This was alleged to be achieved through sham litigation and the filing of a baseless ANDA.
• Antitrust Injury: Valeant claimed that Watson's actions caused it significant financial harm, constituting an antitrust injury for which it sought treble damages.

What were Watson's defenses and counterarguments?

Watson defended against Valeant's allegations by arguing:

• Non-infringement: Watson asserted that its ANDA filing and proposed generic product did not infringe U.S. Patent No. 5,672,596. This defense likely involved arguments that the claimed invention was either not practiced by its product or that the patent was invalid.
• Invalidity of Valeant's Patent: Watson may have challenged the validity of U.S. Patent No. 5,672,596 on grounds such as anticipation, obviousness, or lack of enablement, although specific details of these challenges are not the primary focus of the summarized proceedings.
• No Monopoly Power: Watson likely argued that it did not possess monopoly power in the relevant market and that its actions were not anticompetitive.
• Legitimate Commercial Conduct: Watson contended that its actions, including patent litigation and ANDA filings, were legitimate exercises of its rights and not designed to unlawfully stifle competition.

What was the procedural history of the case?

The litigation, filed in the United States District Court for the Southern District of Florida (Case No. 1:10-cv-20526), involved a complex series of filings, including a complaint by Valeant, Watson's answer and counterclaims, and subsequent motions. Key procedural developments included:

• Complaint Filing: Valeant initiated the lawsuit, outlining its claims of patent infringement and antitrust violations.
• Answer and Counterclaims: Watson responded with its defenses and potentially its own claims against Valeant.
• Motions Practice: The case likely saw extensive motions practice, including motions to dismiss, motions for summary judgment, and motions related to discovery.
• Settlement Discussions: While the litigation was ongoing, there may have been periods of settlement discussions. However, the ultimate resolution did not stem from a fully adjudicated trial on all counts.

How did the antitrust claims evolve and what was the outcome?

The antitrust claims were a significant aspect of the litigation. Valeant's allegations of sham litigation and baseless ANDA filings were central to its Section 2 Sherman Act claims. The U.S. Supreme Court's decision in Professional Real Estate Investors, Inc. v. Columbia Pictures Industries, Inc. (PRE) established a two-part test for determining if litigation is a "sham." To qualify as a sham, the lawsuit must be objectively baseless, meaning that no reasonable litigant could realistically expect success on the merits, and subjectively intended to interfere with a competitor's business relationships.

In this case, the court grappled with whether Watson's actions met the PRE standard. While the exact reasoning for the final disposition of the antitrust claims is complex and involved subsequent appeals and reconsiderations, the general trajectory was that the antitrust claims faced significant hurdles.

A critical development was the eventual settlement of the patent dispute. While the specific terms of the settlement are not publicly detailed in the same way as a court judgment, settlements typically involve mutual concessions and a resolution of the underlying disputes, often including a withdrawal of claims.

What was the outcome of the patent infringement claims?

The patent infringement claims, which were at the heart of the dispute, were ultimately resolved through a settlement. While the details of the settlement are confidential, it is understood that the parties reached an agreement that concluded the patent dispute. This settlement likely involved an agreement regarding the launch and marketing of generic methylnaltrexone bromide.

What was the significance of the settlement?

The settlement between Valeant and Watson had several key significances:

• Resolution of Patent Dispute: It ended the protracted legal battle over U.S. Patent No. 5,672,596, preventing a potentially lengthy and costly trial.
• Impact on Generic Entry: The terms of the settlement would have dictated when and under what conditions a generic version of methylnaltrexone bromide could enter the market, influencing competition and drug pricing.
• Avoidance of Antitrust Trial: By settling the patent dispute, the parties likely avoided a trial on the highly complex and fact-intensive antitrust claims, which carried the risk of substantial damages, including treble damages for Valeant.
• Business Certainty: The settlement provided a degree of business certainty for both companies regarding the future market for methylnaltrexone bromide.

What is the current status of Relistor and its generics?

Following the litigation and settlement, generic versions of methylnaltrexone bromide have become available in the market. Relistor, as the branded product, continues to be marketed. The presence of generics has introduced competition, which typically leads to a reduction in the price of the drug compared to its period of exclusivity. The market dynamics have shifted from a sole-provider scenario to one with multiple players, including both the originator and generic manufacturers.

What were the financial implications of the litigation?

The financial implications of this litigation for both Valeant and Watson were substantial, even without a full trial and judgment. Legal fees associated with complex patent and antitrust litigation are exceptionally high, often running into millions of dollars for each party. Furthermore, the uncertainty surrounding the outcome of the litigation could have impacted the companies' stock prices and investment decisions. For Valeant, a loss on the patent claims could have meant a loss of market exclusivity and significant revenue. For Watson, an adverse ruling on the antitrust claims could have resulted in substantial treble damages. The settlement, while confidential, represents a negotiated outcome that parties believed was more favorable than the potential risks and costs of continued litigation.

Key Takeaways

• The Valeant International, Bermuda v. Watson Pharmaceuticals Inc. litigation concerned patent infringement and antitrust allegations related to the drug methylnaltrexone bromide, with Valeant holding U.S. Patent No. 5,672,596.
• Valeant claimed Watson infringed its patent and violated Section 2 of the Sherman Act through sham litigation and a baseless ANDA filing.
• Watson defended on grounds of non-infringement, patent invalidity, and legitimate commercial conduct.
• The case was resolved through a confidential settlement, concluding the patent infringement dispute.
• The settlement avoided a trial on the complex antitrust claims, which alleged monopolization through anticompetitive practices.
• Generic versions of methylnaltrexone bromide are now available, reflecting the impact of the settlement on market competition.
• The litigation incurred significant legal costs for both parties and involved complex legal standards, including the "sham litigation" test from Professional Real Estate Investors, Inc. v. Columbia Pictures Industries, Inc..

FAQs

1. What was the drug at the center of the Valeant v. Watson patent dispute?

The drug was methylnaltrexone bromide, marketed by Valeant under the brand name Relistor. The dispute involved allegations of patent infringement and anticompetitive practices related to this specific active pharmaceutical ingredient.

2. Did the litigation result in a court judgment finding patent infringement or antitrust violations?

No, the litigation did not proceed to a final court judgment on the core patent infringement and antitrust claims. The parties reached a confidential settlement that resolved the dispute, thus avoiding a trial and judgment on these matters.

3. What is the current market status of methylnaltrexone bromide following the litigation?

Following the settlement, generic versions of methylnaltrexone bromide have entered the market, increasing competition. Relistor, the branded product, continues to be available, but the market now includes multiple generic competitors.

4. What is "sham litigation" in the context of antitrust law?

Sham litigation, as defined by the Supreme Court in Professional Real Estate Investors, Inc. v. Columbia Pictures Industries, Inc., refers to litigation that is objectively baseless and subjectively intended to interfere with a competitor's business relationships. Such litigation can be considered an anticompetitive act under antitrust laws.

5. Who acquired Watson Pharmaceuticals and how does this impact the ongoing legal legacy of the case?

Watson Pharmaceuticals was acquired by Allergan plc. Subsequently, Allergan was acquired by AbbVie Inc. While the corporate entities have changed through mergers and acquisitions, the legal responsibilities and legacy of the litigation remain tied to the entities involved at the time of the disputes, potentially tracing through the acquiring companies.

Citations

[1] Valeant International, Bermuda v. Watson Pharmaceuticals Inc., No. 1:10-cv-20526 (S.D. Fla.). [2] Professional Real Estate Investors, Inc. v. Columbia Pictures Industries, Inc., 508 U.S. 49 (1993).